Mayo Clinic has inked a deal with biosensor developer Gentag that will focus on the needs of patients with diabetes and obesity, according to a statement from the provider. It marks Gentag’s first collaboration with a provider.
The terms of the agreement involve Mayo and Gentag working with third parties under license to develop next generation wearable skin patch technologies from Gentag for diabetes and obesity management. The patent agreement with Mayo will license Mayo and Gentag joint IP and know-how will be licensed to third parties that will actually deploy the technology.
Gentag’s skin patch for diabetes is designed to help remotely monitor glucose levels The biosensor is part of a wearable patch that communicates in a closed-loop diabetes management system compatible with mobile phones.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The system will allow researchers to monitor movement and develop treatments for obesity and related conditions.
Gentag CEO and founder John Peeters said in response to emailed questions that the collaboration also involves creating a communication chip that combines Mayo’ Micro-Miniature Transceiver chip with a radar responsive tag developed by Gentag. “The communication chip will enable low power Body Area Networks that can read through tissue, geolocation and long-range communication.”
Peeters said a number of sensors are not expected to need FDA clearance but some sensors, like those for diabetes, are expected to require clearance.
“The clearance process will be undertaken by the licensees of the technology and it is difficult to assess how long this process will be at this time,” Peeters said.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The technologies are intended to be low cost, painless and disposable so they can be used on a global scale.
